Therefore, new treatment concepts including microsatellite instability (MSI) and KRAS or BRAF mutations have become an area of focus for identifying the genetic causes of CRC and improving personalized medicine for CRC patients [3, 4]. This evidence concerns the gene BRAF and colorectal carcinoma.